Showing 1 posts of 1 posts found.
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
Europa Biosite enters Czech market with acquisition of diagnostics distributor
Qureight paper argues for fibrosis extent as imaging biomarker in lung disease trials
START and Rome cancer institute partner to expand early-phase trial access in Italy
AbbVie expands Oxford R&D facility with new £120m UK research commitment
MedPharm appoints Jason Mieding as chief operating officer